Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.39 |
| ▸ | AURKA | O14965 | 11/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.39 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 5/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 4/20 | 0.35 |
| ▸ | BCR | P11274 | 3/20 | 0.35 |
| ▸ | PLK1 | P53350 | 2/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 3/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982838 | 0.84 | NTRK1 (0.44) | NTRK1NTRK3NTRK2AURKAAURKB | |
| SCHEMBL3485523 | 0.83 | NTRK1 (0.39) | NTRK1NTRK3NTRK2AURKAAURKB | |
| SCHEMBL3485360 | 0.83 | NTRK1 (0.38) | NTRK1NTRK3NTRK2AURKAAURKB | |
| SCHEMBL1982775 | 0.82 | F10 (0.39) | NTRK1NTRK3NTRK2AURKAAURKB | |
| Trifluoroacetic Acid SCHEMBL3485220 | 0.81 | CCNA2 (0.54) | NTRK1NTRK3NTRK2AURKAAURKB | |
| SCHEMBL3485261 | 0.81 | NTRK1 (0.38) | NTRK1NTRK3NTRK2AURKAAURKB | |
| SCHEMBL1982354 | 0.68 | NTRK1 (0.60) | NTRK1NTRK3NTRK2AURKAAURKB | |
| SCHEMBL1984780 | 0.67 | CCNA2 (0.58) | NTRK1NTRK3NTRK2AURKAAURKB | |
| Trifluoroacetic Acid SCHEMBL3485517 | 0.67 | NTRK1 (0.53) | NTRK1NTRK3NTRK2CDK2CCNA2 | |
| SCHEMBL1989764 | 0.66 | CCNA2 (0.59) | NTRK1NTRK3NTRK2AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010008-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-14 | — | — | US | claimed |
| EP-2089394-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2009-08-19 | — | — | EP | claimed |
| WO-2008043745-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-04-17 | — | — | WO | claimed |
| US-8623876-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-01-07 | — | — | US | disclosed |
| US-20120277248-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-01 | — | — | US | disclosed |
| US-8227472-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-07-24 | — | — | US | disclosed |
| US-20100010008-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-14 | — | — | US | disclosed |
| EP-2089394-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008043745-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010008-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | MAP3K5, MAP3K3, MAP3K15 | NTRK1 1290/4885NTRK3 1078/4885NTRK2 2021/4885 |
| US-20120277248-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | MAP3K5, MAP3K3, MAP3K15 | NTRK1 1290/4885NTRK3 1078/4885NTRK2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.